Shilpa Medicare Limited, a research-led global integrated pharmaceutical company, has announced that it has received an in-principle approval from Defence Research & Development Organisation (DRDO) to manufacture and sell 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for COVID-19 patients in the country. Shilpa Medicare Limited is only the second company in India to have entered into a similar arrangement with DRDO.

Shilpa has been continuously striving to contribute towards the fight against COVID-19 and this is yet another step by Shilpa after its recently announced arrangement for manufacture and supply of Sputnik V vaccine.

Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The commercial production in SML started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying affordable API and Formulation globally in different regulated markets.